Skip to main content
. 2017 Apr 24;8(33):54537–54547. doi: 10.18632/oncotarget.17384

Figure 3.

Figure 3

Receiver operating characteristic (ROC) analysis using (A) only clinical variables, (B) clinical variables with ALU cell-free DNA integrity and (C) clinical variables with LINE1 cell-free DNA integrity to estimate the strength of the model to discriminate two groups, along with area under the curve (AUC) and 95% confidence interval (CI).